Technology Org lists a research challenge aimed at getting peptides absorbed by mouth at more than 4% bioavailability.
Recap by typeshit. Full story at Technology Org.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
The lineup covers investigational obesity drugs, real-world Wegovy results and semaglutide studies in kids aged 6 to under 12.
TikTok's health content rules bar weight-management claims and GLP-1 promos, with removals or account penalties for creators who break them.
Loading…